APOE and Alzheimer disease: Findings also suggest this alteration in BOLD-LFOs may be observed in the very earliest stages of AD pathophysiological change, as evidenced by decreased BOLD-LFO power in amyloid-β positive APOE4 carriers relative to amyloid-β negative APOE4 carriers.